EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer

Masahiro Hashimoto iD, Takaaki Masuda iD, Yusuke Nakano, Taro Tobo, Hideyuki Saito, Kensuke Koike iD, Junichi Takahashi, Tadashi Abe, Yuki Ando, Yuki Ozato, Kiyotaka Hosoda, Satoshi Higuchi und 9 weitere

Cancer Science · 2024

DOI: 10.1111/cas.16129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Masahiro Hashimoto und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Transcription Factors, Gene Expression Regulation, Neoplastic, Epigenesis, Genetic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Takeda Science Foundation, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bromodomain and extraterminal domain (BET) family proteins are epigenetic master regulators of gene expression via recognition of acetylated histones and recruitment of transcription factors and co‐activators to chromatin. Hence, BET family proteins have emerged as promising therapeutic targets in cancer. In this study, we examined the functional role of bromodomain containing 3 (BRD3), a BET family protein, in colorectal cancer (CRC). In vitro and vivo analyses using BRD3 ‐knockdown or BRD3‐overexpressing CRC cells showed that BRD3 suppressed tumor growth and cell cycle G1/S transition and induced p21 expression. Clinical analysis of CRC datasets from our hospital or The Cancer Genome Atlas revealed that BET family genes, including BRD3 , were overexpressed in tumor tissues. In immunohistochemical analyses, BRD3 was observed mainly in the nucleus of CRC cells. According to single‐cell RNA sequencing in untreated CRC tissues, BRD3 was highly expressed in malignant epithelial cells, and cell cycle checkpoint‐related pathways were enriched in the epithelial cells with high BRD3 expression. Spatial transcriptomic and single‐cell RNA sequencing analyses of CRC tissues showed that BRD3 expression was positively associated with high p21 expression. Furthermore, overexpression of BRD3 combined with knockdown of, a driver gene in the BRD family, showed strong inhibition of CRC cells in vitro. In conclusion, we demonstrated a novel tumor suppressive role of BRD3 that inhibits tumor growth by cell cycle inhibition in part via induction of p21 expression. BRD3 activation might be a novel therapeutic approach for CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsTranscription FactorsGene Expression Regulation, NeoplasticEpigenesis, GeneticHumansAnimalsMiceCell Line, TumorCyclin-Dependent Kinase Inhibitor p21Cell ProliferationFemaleMaleBromodomain Containing Proteins

Stichwörter der Autor:innen

bromodomain and extraterminal domain (BET)bromodomain containing 3 (BRD3)cell cyclecell growthcolorectal cancer

Substanzen

Transcription FactorsBRD3 protein, humanCyclin-Dependent Kinase Inhibitor p21CDKN1A protein, humanBromodomain Containing Proteins

Autor:innen und Institutionen

  • Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
  • Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
  • Department of Pathology, Kyushu University Beppu Hospital, Beppu, Japan.
  • Tokai University School of Medicine, Isehara, Japan.

ORCID-Profile: Masahiro Hashimoto, Takaaki Masuda, Kensuke Koike, Takeo Toshima, Hidetoshi Eguchi, Koshi Mimori

Förderung

  • Japan Agency for Medical Research and Development
  • Takeda Science Foundation
  • Japan Society for the Promotion of Science
  • Princess Takamatsu Cancer Research Fund
  • OITA Cancer Research Foundation

Zitieren

APA

Hashimoto, M., Masuda, T., Nakano, Y., Tobo, T., Saito, H., Koike, K., Takahashi, J., Abe, T., Ando, Y., Ozato, Y., Hosoda, K., Higuchi, S., Hisamatsu, Y., Toshima, T., Yonemura, Y., Hata, T., Uemura, M., Eguchi, H., Doki, Y., …, & Mimori, K. (2024). Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer. Cancer Science. https://doi.org/10.1111/cas.16129

Vancouver

Hashimoto M, Masuda T, Nakano Y, Tobo T, Saito H, Koike K, et al. Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer. Cancer Science. 2024. doi:10.1111/cas.16129

BibTeX
@article{Hashimoto2024,
  author = {Hashimoto, Masahiro and Masuda, Takaaki and Nakano, Yusuke and Tobo, Taro and Saito, Hideyuki and Koike, Kensuke and Takahashi, Junichi and Abe, Tadashi and Ando, Yuki and Ozato, Yuki and Hosoda, Kiyotaka and Higuchi, Satoshi and Hisamatsu, Yuichi and Toshima, Takeo and Yonemura, Yusuke and Hata, Tsuyoshi and Uemura, Mamoru and Eguchi, Hidetoshi and Doki, Yuichiro and Mori, Masaki and Mimori, Koshi},
  title = {Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16129}
}
Kostenlos starten →